Tumour tissue collection for Gynecologic Cancers

Recruiting · 18+ · Female · Toronto, Canada

This study is evaluating whether a drug that may be able to block certain specific cancer cell changes is called "targeted therapy".

See full description

About the trial for Gynecologic Cancers

Treatment Groups

This trial involves 2 different treatments. Tumour Tissue Collection is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Blood draws
Tumour tissue collection
Tumor tissue collection
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
Blood draws
Completed Phase 2


This trial is for female patients aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
therapy will be enrolled People who are probably diagnosed with a gynecological cancer and are undergoing surgery or radiation therapy will be enrolled in the study. show original
Minimum weight = 50 kilograms The patient must be 16 years or older at the time of consent and weigh at least 50 kilograms. show original
Ability to understand and agree to information disclosed orally. show original
The individual has a good performance status, as defined by the ECOG scale, of ≤ 2. show original
The patient must consent to providing tissue samples from surgery and blood samples. show original
Life expectancy ≥3 months.
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 5 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 5 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Tumour tissue collection will improve 2 primary outcomes in patients with Gynecologic Cancers. Measurement will happen over the course of 5 years.

Genomic and immune signatures in terms of overall survival
Genomic and immune signatures in terms of progression free survival

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who should consider clinical trials for gynecologic cancers?

Overall, the authors concluded that clinical trials are a viable option for patients. For patients with advanced or recurrent disease and no active life-threatening illnesses, there were no differences in survival or duration of survival within the three treatment groups—surgery alone, surgery with adjuvant chemotherapy, or surgery + adjuvant chemotherapy.

Anonymous Patient Answer

What causes gynecologic cancers?

The exact cause of gynecologic cancer is unknown. Factors that correlate with the development thereof are: age at the time of diagnosis, female breast feeding, estrogen receptor status, estrogen-producing cancers, cervical lesions, uterine leiomyoma, and pregnancy. Smoking seems to be linked to many of these associations.

Anonymous Patient Answer

Can gynecologic cancers be cured?

Many patients with gynecologic cancers will live long and active lives despite disease progression, and, in some cases, the disease is still in remission at the time of the survey.

Anonymous Patient Answer

What are common treatments for gynecologic cancers?

Clinicians are faced with a difficult decision between chemotherapy and radiotherapy: two main treatments for gynecologic cancers. Although radiotherapy is generally a first-line treatment, it is often delayed so that chemotherapy is administered. Clinical trials may be the fastest way to tell us the value of chemotherapy plus radiotherapy. This review of available data has revealed that radiotherapy was commonly used before chemotherapy; it was also indicated that the results of most published research supports the effectiveness of radiotherapy alone; chemotherapy plus systemic treatment is now preferred in almost all trials; chemotherapy is preferable at least to radiotherapy in combination with surgery; chemotherapy plus local radiotherapy is considered a reasonable first-line treatment.

Anonymous Patient Answer

What are the signs of gynecologic cancers?

The most common signs of gynecologic cancers are pain with urination, unexplained weight loss, and vaginal bleeding or discharge. The most unusual sign of cancer is an enlarged, firm thigh mass, which, if found in women as young as 20 years of age, is more likely to be a type of cancer.

Anonymous Patient Answer

What is gynecologic cancers?

Although this patient population is at a higher risk for developing [ovarian cancer](, the 5-year survival for patients with benign ovarian neoplasms is high compared with that of patients with malignant gynecologic neoplasms. The current treatments are optimized before and after surgery, and they decrease morbidity and mortality regardless of the histologic subtype and stage of the cancers. If patients can choose a course of care that emphasizes the most effective approach, the prognosis is improved; however, the optimal treatment approach is undefined.

Anonymous Patient Answer

How many people get gynecologic cancers a year in the United States?

Approximately 5,250 women (0.8%) and 15,250 men (2.5%) will be diagnosed with primary or metastatic [uterine cancer]( annually, accounting for about 12.7 million total new cancer cases, of which 4.7 million will be females.

Anonymous Patient Answer

Has tumour tissue collection proven to be more effective than a placebo?

Recent findings refute the conclusion that tumour tissue donation increases the rate of tumour recurrence when compared to a placebo in women having a total radical hysterectomy for gynaecological cancer. This trial was registered with (CRT Number: ISRCTN 60920861).

Anonymous Patient Answer

What are the latest developments in tumour tissue collection for therapeutic use?

Tissue collection continues to expand and now include most tumour types. It seems the future may see increased use of ex-vivo tissue and other advanced regenerative technologies to develop a Tissue Procurement Unit as a key component of any cancer centre.

Anonymous Patient Answer

Have there been any new discoveries for treating gynecologic cancers?

Recent studies have been reported. Research for targeting therapeutic agents is underway; specifically, clinical trials are designed for [ovarian cancer](, cervical cancer, and uterine leiomyoma, which are commonly diagnosed in the United States. In addition to studies that target individual cancers, studies have also been conducted to identify the specific role of the microenvironment in these cancers; these findings will enable future therapeutics that use more personalized treatments.

Anonymous Patient Answer

Is tumour tissue collection typically used in combination with any other treatments?

Collected tumour tissue samples should be used for research only if a high level of confidence in the results can be assured. Therefore, the use of metastatic tumours should be avoided.

Anonymous Patient Answer

What is the average age someone gets gynecologic cancers?

[Gonorrhea infections are most commonly seen in women between the ages of 10-30 years of age. And more than half of the cases will heal, but symptoms reappear. After 1 year, gonorrhea reappears in 8 of 29 cases (27%) and 15.5 years on average, and the most common symptoms were: itching, pain, irritation during sexual activity, and bleeding. A new set of symptoms appear when the disease recurs for about 1-to-2 years.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Gynecologic Cancers by sharing your contact details with the study coordinator.